4,901 trials
Non-Small Cell Lung Cancer · Metastatic Melanoma · Acute Myeloid Leukemia
Primary: Total Radioactivity - Plasma Maximum Observed Concentration (Cmax) — 81.2 ngEq/mL
Cancer · Solid Tumor
Primary: Module 1 - Safety and Tolerability of RXC004 by Assessment of Whether Any Dose Limiting Toxicities (DLT) Arise From First Dose Until the End of 21 Days of Continuous…
Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma Activated B-Cell Type · Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Primary: Maximum Tolerated Dose (MTD) — 100 mg TAK-659
Malaria,Falciparum
Primary: Number of Treatment-Emergent Adverse Events (TEAEs) — 1; 4; 5; 1 Number of events
Helicobacter Pylori Infection
Primary: Safety of TNP-2092 by Assessment of the Number of Adverse Events (AEs) — 6; 9; 4; 3 participants
NAFLD
Primary: Number of Participants With Adverse Events — 7; 9; 9; 8 Participants
Leukemia, Myeloid, Acute
Primary: Determination of the Maximum Tolerated Dose (MTD) of BI 836858 — NA; NA Milligram (mg)
COVID-19
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAT) — 1; 3; 7 Participants
HIV-1 Infection
Primary: Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) — 0; 0 percentage of participants
Intestinal Diseases
Primary: Maximum Plasma Concentration (Cmax) of Albendazole — 43.846; 41.685; 39.737; 46.115 nanogram/millilitre (ng/mL)
Obese With Comorbidities · Overweight With Comorbidities · Type2 Diabetes
Primary: To Evaluate the Incidence of AEs — 1; 2; 4; 2 Participants
Safety and Tolerability
Primary: Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions — 1; 2; 3; 2 Participants
Breast Cancer · Urothelial Carcinoma
Primary: Number of Participants With Dose-Limiting Toxicities at 3.2 mg/kg and 5.4 mg/kg Dose Level in Participants With HER2-expressing Advanced Breast Cancer in Dose Escalation…
Drug Drug Interaction
Primary: Plasma Pharmacokinetic (PK) Parameters of Givinostat, Following First Single-dose Administration of Givinostat: Cmax — 48.06; 7.34; 132.20; 88.77 ng/mL
Advanced and Metastatic Solid Tumor
Primary: The Number of Dose Limiting Toxicity (DLT) for RD Determination — 0; 0; 3; 5 Participants